Abstract
Chemoradiation is a potential treatment option for muscle-invasive bladder cancer for low-volume focal disease or limited disease, those individuals who desire bladder preservation, or those who are medically unfit for cystectomy. Ideal candidates are patients with an organ-confined solitary tumor, therefore without multifocal disease, or carcinoma in situ, hydronephrosis, or mixed histology. Trimodal therapy is considered the most comprehensive strategy for a select group of patients and associated with favorable oncologic outcomes. Maintenance of bladder function and the goal of treatment response is key in choosing a management strategy. Preservation of quality of life is often a motivating factor for patients in choosing trimodal therapy (TMT). Survivorship is managed collaboratively by the genitourinary disciplines inclusive of urologists, medical oncologists, radiation oncologists, and advanced practice providers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Antoni S, Ferlay J, Soejomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.
Siegel RL, Miller KD, Jemel A. Cancer statistics, 2020. Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.
Prout GR, Marshall VF. The prognosis with untreated bladder tumors. Cancer. 1956;9:551–8.
Pietzak EJ, Sterling ME, Smith ZL, Malkowicz SB, Guzzo TJ. Outcomes of radical cystectomy in potential candidates for bladder preservation therapy. Oncology. 2015;85(4):869–75. https://doi.org/10.1016/j.urology.2015.01.001.
Hall E, Hussain SA, Porta N, et al. BC2011 long-term outcomes: a phase III randomized trial of chemoradiotherapy versus radiotherapy alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer. J Clin Oncol. 2017;35(Suppl 6S):280.
James ND, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.
El-Achkar A, Souhami L, Kassouf W. Bladder preservation therapy: review of literature and future directions of trimodal therapy. Curr Urol Rep. 2018;19(108):1–10. https://doi.org/10.1007/s11934-018-0859-z.
Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rodel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–37.
Herr H. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001;19(1):89–93.
Mazza P, Moran GW, Li G, Robins DJ, Matulay JT, Herr HW, Decastro GJ, McKiernan JM, Anderson CB. Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study. J Urol. 2018;200(5):1005–2013. https://doi.org/10.1016/j.juro.2018.05.078.
Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur J Urol. 2017;72(1):54–60.
Zeitman AL, Hunt D, Kauffman DS, et al. Preliminary results of RTOG 0233: a phase II randomized trial for muscle-invading bladder cancer treated by transurethral resection and radiotherapy comparing two forms of concurrent induction chemotherapy. Int J Radiat Oncol Biol Phys. 2010;78(3Suppl):S31–2.
Mirza A, Choudhury A. Bladder preservation for muscle invasive bladder cancer. Bladder Cancer. 2016;2:151–63. https://doi.org/10.3233/BLC-150025.
Cahn DB, Ristau BT, Ghiraldi EM, Churilla TM, Geynisman DM, Horwitz EM, Uzzo RG, Smaldone MC. Bladder preservation therapy: a review of the literature and future directions. Urology. 2016;96:54–61. https://doi.org/10.1016/j.urology.2016.05.041.
Smith Z, Christoudouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int. 2013;112:13–25. https://doi.org/10.1111/j.1464-410X.201211762.x.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Caruso, A.M., Guzzo, T.J. (2021). Chemoradiation Bladder Preservation. In: Trabulsi, E.J., Lallas, C.D., Lizardi-Calvaresi, A.E. (eds) Chemotherapy and Immunotherapy in Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-52021-2_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-52021-2_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-52020-5
Online ISBN: 978-3-030-52021-2
eBook Packages: MedicineMedicine (R0)